Return
Cat. #:101-33
Recombinant Human Interleukin-33
rHuIL-33
Technical Parameters
SynonymsIL-1F11, NF-HEV, DVS 27
Species9
AccessionO95760
GeneID90865
Source Escherichia coli.
Molecular Weight Approximately 17.9 kDa, a single non-glycosylated polypeptide chain containing 159 amino acids.
Quantity 2µg/10µg/1000µg
AA Sequence SITGISPITE YLASLSTYND QSITFALEDE SYEIYVEDLK KDEKKDKVLL SYYESQHPSN ESGDGVDGKM LMVTLSPTKD FWLHANNKEH SVELHKCEKP LPDQAFFVLH NMHSNCVSFE CKTDPGVFIG VKDNHLALIK VDSSENLCTE NILFKLSET
Purity > 97 % by SDS-PAGE and HPLC analyses.
Biological Activity Fully biologically active when compared to standard. The ED50 as determined by a cell proliferation assay using murine D10S cells is less than 0.05 ng/ml, corresponding to a specific activity of > 2.0 × 107 IU/mg.
Physical Appearance Sterile Filtered White lyophilized (freeze-dried) powder.
Formulation Lyophilized from a 0.2μm filtered concentrated solution in 20 mM PB, 150 mM NaCl, 1mM EDTA, pH7.4.
Endotoxin Less than 1 EU/µg of rHuIL-33 as determined by LAL method.
Reconstitution We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Usage This material is offered by Shanghai PrimeGene Bio-Tech for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE.
SDS-PAGE
Reference1. Liew FY, Pitman NI, McInnes IB. 2010. Nat Rev Immunol, 10: 103-10.
2. Miller AM, Xu D, Asquith DL, et al. 2008. J Exp Med, 205: 339-46.
3. Bourgeois E, Van LP, Samson M, et al. 2009. Eur J Immunol, 39: 1046-55.
4. Zhiguang X, Wei C, Steven R, et al. 2010. Immunol Lett, 131: 159-65.
5. Turnquist HR, Zhao Z, Rosborough BR, et al. 2011. J Immunol, 187: 4598-610.
BackgroundIL-33, encoded by IL-33 gene located on the Chr.9 in humans, is a 30 kDa proinflammatory protein belonging to the IL-1 superfamily and it shares less than 20 % a.a. sequence identity with other members. IL-33 secreted by high endothelial venules at high levels, which is found in tonsils, peyer patches and mesenteric lymph nodes, but not in placenta. It is upregulated in arterial smooth muscle, dermal fibroblasts, and keratinocytes following IL1α or IL1β stimulation. It elicits its biological effects by interacting with IL1RL1/ST2 and its stimulation recruits MYD88, IRAK1, IRAK4, and TRAF6, followed by phosphorylation of MAPK3/ERK1 and/or MAPK1/ERK2, MAPK14, and MAPK8. IL-33 mature protein has 52-58 % a.a. sequence identity with mouse and rat IL-33.